Article Text

Download PDFPDF
Cardiovascular safety of febuxostat and allopurinol

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The authors of a randomised controlled study have reported that secondary outcome measures of all-cause mortality and cardiovascular mortality were higher with febuxostat than with allopurinol.1 Although prospective studies have suggested that gout is associated with increased mortality from cardiovascular disease, a causal relationship has not been firmly established.2 Nevertheless, the finding that the risk of cardiovascular events is higher in people with gout has led to investigations of the cardiovascular safety of gout therapies.1 In addition, the USA Food and Drug Administration (FDA) has investigated reports of …

View Full Text